| ATTRIBUTES | BIVALENT (CERVARIXÒ) | QUADRIVALENT (GARDASILÒ/SILGARDÒ) | 9-VALENT (GARDASIL 9Ò) |
| Vaccine type | Recombinant L1-capsid virus-like particles (VLP) | Recombinant L1-capsid virus-like particles (VLP) | Recombinant L1-capsid virus-like particles (VLP) |
| HPV types | 16, 18 | 6, 11, 16, 18 | 6, 11, 16, 18 31, 33, 45, 52, 58 |
| Disease protection | Cervical cancer (and premalignant genital lesions of cervix, vulva and vagina) | Cervical cancer (and premalignant genital lesions of cervix, vulva and vagina), Genital warts | Cervical cancer (and premalignant genital lesions of cervix, vulva and vagina), Genital warts |
| Age of vaccination | 9 - 14 | 9 - 13 | 9 - 14 |
| Number of doses required | 2 | 2 | 2 |
| Dosing interval | 0 and 6 months (No maximum interval but suggested not more than 12 - 15 months) | 0 and 6 months (No maximum interval but suggested not more than 12 - 15 months) | 0 and 6 months (No maximum interval but suggested not more than 12 - 15 months) |